ReviewRSC medicinal chemistry2025
Naphthalimide-organometallic hybrids as multi-targeted anticancer and luminescent cellular imaging agents.
Review in RSC medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- DPPZ-Naphthalimide Conjugates as G-Quadruplex DNA Targeting Scaffolds: Design, Synthesis and Biomolecular Interaction Studies.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Benzodioxin-Annulated Naphthalimides as Potent DNA Replication Stress Inducers with Dual p53-Dependent and Independent Antitumor Activity.Pharmaceutics · 2026Article
- Assessment of the Biological Properties ofMolecules (Basel, Switzerland) · 2025Article
- Photodynamic Microbial Defense of Cotton Fabric with 4-Amino-1,8-naphthalimide-Labeled PAMAM Dendrimer.Materials (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1,8-Naphthalimides with an organometallic moiety with anticancer and luminescence or photoactive properties are reviewed. Primarily highlighted are 1,8-naphthalimide complexes with iron, platinum, and ruthenium, while honourable mentions are given to iridium, rhenium and rhodium complexes. The cytotoxicity, mechanism of action and cell selectivity of the compounds are discussed alongside their photophysical properties for monitoring interactions with biomolecules, most notably DNA, by absorption, fluorescence and dichroism spectroscopy. The luminescence properties provide additional insight regarding the cellular uptake and location of the intelligent agents within both cancer and healthy cells. The versatility of this emerging hybrid class of molecules earmarks them as multi-functional therapeutic and cellular imaging agents. The review concludes with suggestions for designing more effective multi-targeting cytotoxic agents with improved biocompatibility and imaging in hopes of enhancing their clinical potential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.